Last reviewed 2026-04-20 · How we verify

Meropenem extended infusion

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Anaemia
• Alanine aminotransferase increased
• Diarrhoea
• Hypokalaemia
• Aspartate aminotransferase increased
• Pyrexia
• Hepatic function abnormal
• Nausea
• Vomiting
• Constipation
• Pleural effusion
• Rash

Key clinical trials

• A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
• Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections (PHASE3)
• EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS (PHASE4)
• Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii (PHASE4)
• Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
• Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections. (NA)
• PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock (PHASE3)
• Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Meropenem extended infusion CI brief — competitive landscape report
• Meropenem extended infusion updates RSS · CI watch RSS
• Austin Health portfolio CI